Teradyne director sells $270K in company stock
A TERADYNE, INC director sold 800 shares under a pre-arranged Rule 10b5-1 trading plan and continues to hold over fourteen thousand shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
TERADYNE, INC (TER) director Marilyn Matz reported selling 800 shares of common stock on September 15, 2026 at about $337.83 per share in an open-market or private transaction. The sale was made under a Rule 10b5-1 sales plan adopted on February 13, 2026, and she now holds 14,240.675 shares directly.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 800 | $337.83 | $270K |
Footnotes (1)
- F1. The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person on February 13, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
Key Figures
Key Terms
Rule 10b5-1 regulatory
sales plan financial
open market or private transaction financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did TER (Teradyne, Inc) disclose in this Form 4?
Was the recent insider sale in TER (Teradyne, Inc) made under a Rule 10b5-1 plan?
What is the role of the reporting person in TER (Teradyne, Inc)?
How many TER (Teradyne, Inc) insider sales are reported in this Form 4 filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.